Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
26 results
Search Results
Item Long Term Effects Of Eplerenone Treatment In Children With Chronic Allograft Dysfunction(2022) Baskin, Esra; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Ozdemir, B. Handan; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0003-0774-4419; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; F-3294-2013; AAD-1877-2021; AAC-5566-2019; AAJ-8097-2021Item Assessment Of Long-Term Outcomes Of Pediatric Liver Transplant Recipients(2022) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Ozcay, Figen; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; AAC-5566-2019; AAJ-8097-2021Item Long Term Outcomes Of Kidney Transplant In Pediatric Recipients(2022) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Baskin, Esra; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; AAC-5566-2019; AAJ-8097-2021Item The Reliability And Validity Study Of Pediatric Transplant Rating Instrument In Turkish Renal Transplant Patients(2022) Taner, Hande Ayraler; Sari, Burcu Akin; Baskin, Esra; Kazanci, Nafia Ozlem; Karakaya, Jale; Gulleroglu, Kaan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; F-3294-2013; AAC-5566-2019; AAJ-8097-2021Item Comparison of Mortality Rates in Patients Waiting for Liver Transplant and Patients With Colorectal Metastatic Tumors(2022) Erkent, Murathan; Aydin, H. Onur; Tezcaner, Tugan; Avci, Tevfik; Kavasoglu, Lara; Soy, Ebru H. Ayvazoglu; Yildirim, Sedat; Haberal, Mehmet; 0000-0002-3592-5092; 0000-0002-0664-5147; 0000-0002-0993-9917; 0000-0002-3462-7632; 35352633; CAA-2756-2022; AAJ-8219-2021; AAC-5566-2019; AAJ-8097-2021Objectives: We aimed to identify outcomes of liver surgery in patients with hepatocellular carcinoma and colorectal cancer, which result in primary and secondary liver tumors. Materials and Methods: Our study included 51 patients with colorectal cancer and liver metastases and 63 patients with hepatocellular carcinoma who were prepared for liver transplant due to cirrhosis who underwent hepatic resection or local ablation treatments; patients were seen between January 2011 and December 2021. Results: Most patients with colorectal cancer were men (58.8%). Mean age was 65.76 +/- 13.818 years (range, 27-88 y). Most patients had planned, elective surgery (86.3%). Neoadjuvant chemotherapy was administered to 58.8% of patients. The most common location of metastasis in the liver was in the right lobe (43.1%), and the most common surgery was low anterior resection (17 patients). During simultaneous liver surgery, 31 patients required metastasectomy and 7 patients required radiofrequency ablation plus metastasectomy. No deaths occurred in the early posttransplant period, and cumulative survival was 82.624 +/- 7.962 months. Disease-free survival was 45.2 +/- 7.495 months. Most patients with hepatocellular carcinoma were men (82.5%). Mean age was 58.73 +/- 17.428 years. Hepatocellular carcinoma lesions were mostly located in both the right and left lobes (23.8%). In the hepatocellular cancer group, 60.3% had transarterial chemoembolization and 42.9% had radiofrequency ablation. The primary surgical resection was metastasectomy (17.9%) because of multiple localized lesions. Median follow-up was 22 months (range, 1-126 mo). Overall survival was 101.898 +/- 7.169 months, with 10-year overall survival of 38%. Disease-free survival was 74.081 +/- 8.732 months, with 1-year and 5-year disease-free survival of 90.5% and 54%. Conclusions: Better survival was shown in patients with hepatocellular carcinoma than in patients with colorectal cancer. Therefore, more aggressive treatment options, as used in hepatocellular carcinoma, including liver transplant, may be options for patients with colorectal cancer.Item Liver Transplant Experiences For The Budd-Chiarı Syndrome At Baskent University Transplant Centers(2021) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Etik, Digdem Ozer; Boyvat, Fatih; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; AAC-5566-2019; F-4230-2011; AAA-3068-2021; AAJ-8097-2021Item Clinical Outcomes Of Liver Transplantation For Patients Over 60 Years Old; A Single Center Experience(2021) Akdur, Aydincan; Karakaya, Emre; Soy, Ebru H. Ayvazoglu; Karakayali, Feza; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; AAC-5566-2019; AAA-3068-2021; AAJ-8097-2021Item Urinary Tract Infections And Long Term Outcomes After Pediatiıc Renal Transplantation(2021) Baskin, Esra; Akdur, Aydincan; Gulleroglu, Kaan; Karakayali, Feza; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; 0000-0003-1434-3824; AAC-5566-2019; AAA-3068-2021; AAJ-8097-2021; AAJ-8833-2021Item Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant(2020) Rahatli, Samed; Soy, Ebru H. Ayvazoglu; Oguz, Arzu; Altundag, Ozden; Moray, Gokhan; Haberal, Mehmet; 0000-0003-0197-6622; 0000-0002-3462-7632; 0000-0003-2498-7287; 0000-0003-3163-7429; 0000-0001-6512-6534; 0000-0002-0993-9917; 32279656; W-9219-2019; AAJ-8097-2021; AAE-1041-2021; AAJ-3047-2021; W-8004-2019; AAC-5566-2019Objectives: Hepatocellular carcinoma remains a major health problem with increased rates of mortality. The curative treatment options are resection or liver transplant. Because the Milan criteria are restrictive for candidates, they have been expanded into alternative sets of criteria. We aimed to evaluate our indications for liver transplant and their results for hepatocellular carcinoma. Materials and Methods: Between December 1988 and January 2020, we performed 652 liver transplant procedures (443 living donors, 209 deceased donors) at Baskent University (Ankara, Turkey). At Baskent University, we developed liver transplant criteria for patients with hepatocellular carcinoma. For our criteria, liver transplant for hepatocellular carcinoma was performed in patients without major vascular invasion and distant metastasis. Clinical data on cancer demographics, recurrence patterns, and survival outcomes were evaluated retrospectively. Results: Of 652 total patients, 49 adult patients (8%) with diagnosis of hepatocellular carcinoma were included in this study. Median age was 55 years. Hepatocellular carcinoma recurrence after liver transplant was detected in 13 patients. Median overall survival was 64.3 months for all study patients; however, median survival was significantly lower in patients who had recurrence (126.3 vs 43.4 mo for nonrecurrent vs recurrent groups; P = .024). In the expanded criteria group (n = 25), 7 patients (28%) had hepatocellular carcinoma recurrence during follow-up, whereas this ratio was 25% (6/24 patients) in the Milan criteria group, with median time to recurrence of 12.6 versus 11.7 months, respectively (not significantly different). Conclusions: Multidisciplinary treatment modalities, including surgery, interventional radiology techniques, and medical treatments, will probably lead to prolonged survival in patients with hepatocellular carcinoma. According to our center's expanded criteria, recurrence rates and time to recurrence were similar to those shown with the Milan group. We showed that Milan criteria can be safely expanded with promising results even in patients beyond Milan criteria.Item Changes in ocular biometric parameters after renal transplantation(2020) Aksoy, Mustafa; Asena, Leyla; Gungor, Sirel Gur; Soy, Ebru H. Ayvazoglu; Akman, Ahmet; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0002-0993-9917; 0000-0001-6178-8362; 0000-0002-6848-203X; 0000-0003-1513-7686; 32415655; AAJ-8097-2021; AAC-5566-2019; E-5914-2016; AAD-5967-2021Purpose This study aimed to investigate the changes in postoperative ocular biometric parameters in end-stage renal disease patients who underwent renal transplantation. Material and methods This retrospective study included a total of 33 eyes of 33 patients. The ocular biometric measurements which were evaluated were axial length (AL), central corneal thickness (CCT), anterior chamber depth (ACD), corneal keratometry (K1 and K2), degree of astigmatism, lens thickness (LT), and intraocular pressure (IOP). Refractive prediction error (RE) was calculated before and after renal transplantation using the same diopter (D) for intraocular lens (IOL) power calculation and evaluated for potential cataract surgery. Results The study included 15 male (45%) and 18 female (55%) patients. Mean patient age was 31.55 +/- 8.24 (range: 18-49 years). In the comparison of preoperative and 1-month postoperative measurements, there was a statistically significant difference in AL, LT, ACD, and CCT (p < 0.001). There was no statistically significant difference between K1, K2, and astigmatism measurements (p = 0.72; p = 0.35; p = 0.62, respectively). There was no statistically significant difference in RE (p = 0.61-Holladay 2). Conclusion While renal transplantation surgery does not lead to significant changes in astigmatism, predicted refractive error, corneal keratometry, or intraocular pressure, it causes significant decrease in axial length, lens thickness, and central corneal thickness and significant increase in anterior chamber depth. However, these changes do not result in significant changes in IOL power calculation in planned cataract surgery.
- «
- 1 (current)
- 2
- 3
- »